Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.2093 | 1 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.0019 | 0.2093 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0019 | 0.2093 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.2093 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.002 | 0.2558 | 0.2147 |
Echinococcus granulosus | terminal deoxycytidyl transferase rev1 | 0.0019 | 0.2093 | 0.1656 |
Schistosoma mansoni | hypothetical protein | 0.002 | 0.2558 | 0.2822 |
Echinococcus granulosus | dna polymerase kappa | 0.0019 | 0.2093 | 0.1656 |
Schistosoma mansoni | plexin | 0.0035 | 0.7733 | 1 |
Echinococcus granulosus | plexin a4 | 0.0041 | 1 | 1 |
Echinococcus multilocularis | dna polymerase eta | 0.0019 | 0.2093 | 0.1656 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.0019 | 0.2093 | 0.1656 |
Loa Loa (eye worm) | plexin A | 0.0041 | 1 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0019 | 0.2093 | 1 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.0019 | 0.2093 | 0.1656 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0019 | 0.2093 | 0.5 |
Leishmania major | DNA polymerase kappa, putative | 0.0019 | 0.2093 | 0.5 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0019 | 0.2093 | 0.5 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0019 | 0.2093 | 0.5 |
Echinococcus multilocularis | dna polymerase kappa | 0.0019 | 0.2093 | 0.1656 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0019 | 0.2093 | 0.5 |
Giardia lamblia | DINP protein human, muc B family | 0.0019 | 0.2093 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.2093 | 1 |
Brugia malayi | Plexin repeat family protein | 0.0035 | 0.7733 | 0.7608 |
Loa Loa (eye worm) | hypothetical protein | 0.0019 | 0.2093 | 0.1656 |
Onchocerca volvulus | 0.0035 | 0.7733 | 1 | |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.2093 | 1 |
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.0019 | 0.2093 | 0.5 |
Echinococcus granulosus | dna polymerase eta | 0.0019 | 0.2093 | 0.1656 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0019 | 0.2093 | 0.5 |
Schistosoma mansoni | plexin | 0.002 | 0.2558 | 0.2822 |
Echinococcus multilocularis | terminal deoxycytidyl transferase rev1 | 0.0019 | 0.2093 | 0.1656 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0019 | 0.2093 | 1 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0019 | 0.2093 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.2093 | 1 |
Trypanosoma brucei | unspecified product | 0.0019 | 0.2093 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.2093 | 1 |
Schistosoma mansoni | terminal deoxycytidyl transferase | 0.0019 | 0.2093 | 0.2177 |
Loa Loa (eye worm) | ImpB/MucB/SamB family protein | 0.0019 | 0.2093 | 0.1656 |
Echinococcus multilocularis | plexin a4 | 0.0041 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0019 | 0.2093 | 0.5 |
Leishmania major | DNA polymerase kappa, putative,DNA polymerase IV, putative | 0.0019 | 0.2093 | 0.5 |
Entamoeba histolytica | deoxycytidyl transferase, putative | 0.0019 | 0.2093 | 0.5 |
Schistosoma mansoni | rab geranylgeranyl transferase alpha subunit | 0.0019 | 0.2093 | 0.2177 |
Schistosoma mansoni | DNA polymerase eta | 0.0019 | 0.2093 | 0.2177 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.2093 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.2093 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.2093 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0035 | 0.7733 | 0.7608 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.2093 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0019 | 0.2093 | 0.5 |
Leishmania major | DNA polymerase eta, putative | 0.0019 | 0.2093 | 0.5 |
Trichomonas vaginalis | DNA polymerase eta, putative | 0.0019 | 0.2093 | 0.5 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0019 | 0.2093 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI50 (functional) | -5.974 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -5.56 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -5.496 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -5.43 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -5.086 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.957 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.89 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.863 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.733 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.